Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy-Reference-Cited by-同舟云学术

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Published:2018-01-31 Issue:5 Volume:103 Page:770-777
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Goetz Matthew P.¹,Sangkuhl Katrin²,Guchelaar Henk-Jan³,Schwab Matthias⁴⁵⁶,Province Michael⁷,Whirl-Carrillo Michelle²,Symmans W. Fraser⁸,McLeod Howard L.⁹,Ratain Mark J.¹⁰,Zembutsu Hitoshi¹¹,Gaedigk Andrea¹²,van Schaik Ron H.¹³¹⁴,Ingle James N.¹,Caudle Kelly E.¹⁵,Klein Teri E.²

Affiliation:

1. Department of Oncology, Department of Molecular Pharmacology and Experimental Therapeutics; Mayo Clinic; Rochester Minnesota USA

2. Department of Biomedical Data Science; Stanford University; Stanford California USA

3. Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden The Netherlands

4. Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology; Stuttgart Germany

5. Department of Clinical Pharmacology; University Hospital; Tuebingen Germany

6. Department of Pharmacy and Biochemistry; University of Tuebingen; Tuebingen Germany

7. Division of Statistical Genomics; Washington University School of Medicine; St. Louis Missouri USA

8. Department of Pathology; University of Texas MD Anderson Cancer Center; Houston Texas USA

9. Moffitt Cancer Center; Tampa Florida USA

10. Center for Personalized Therapeutics; University of Chicago; Chicago Illinois USA

11. Division of Human Genetics; National Cancer Center, Research Institute; Tokyo Japan

12. Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City and Department of Pediatrics; University of Missouri-Kansas City; Kansas City Missouri USA

13. International Expertcenter Pharmacogenetics, Dept Clinical Chemistry; Erasmus MC Rotterdam The Netherlands

14. LKCH UMC Utrecht; The Netherlands

15. Department of Pharmaceutical Sciences; St. Jude Children's Research Hospital; Memphis Tennessee USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference57 articles.

1. PharmGKB Gene Reference Materials for CYP2D6 https://www.pharmgkb.org/page/cyp2d6RefMaterials 2016

2. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update;Crews;Clin. Pharmacol. Ther.,2014

3. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype;Gaedigk;Clin. Pharmacol. Ther.,2008

4. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin;Crews;Pharmacol. Ther.,2012

5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors;Hicks;Clin. Pharmacol. Ther.,2015

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron;Pharmaceutics;2024-08-17

2. CYP2D6 copy number determination using digital PCR;Frontiers in Pharmacology;2024-08-14

3. Genetic ancestral patterns inCYP2D6alleles: structural variants, rare variants, and clinical associations in 479,144 UK Biobank genomes;2024-07-24

4. Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients;Clinical Pharmacology & Therapeutics;2024-07-22

5. Towards precision cancer medicine for Aboriginal and Torres Strait Islander cancer health equity;Medical Journal of Australia;2024-07